Direct Interrogation of Viral Peptides Presented by the Class I HLA of HIV-Infected T Cells

ABSTRACT Identification of CD8+ cytotoxic T lymphocyte (CTL) epitopes has traditionally relied upon testing of overlapping peptide libraries for their reactivity with T cells in vitro. Here, we pursued deep ligand sequencing (DLS) as an alternative method of directly identifying those ligands that are epitopes presented to CTLs by the class I human leukocyte antigens (HLA) of infected cells. Soluble class I HLA-A*11:01 (sHLA) was gathered from HIV-1 NL4-3-infected human CD4+ SUP-T1 cells. HLA-A*11:01 harvested from infected cells was immunoaffinity purified and acid boiled to release heavy and light chains from peptide ligands that were then recovered by size-exclusion filtration. The ligands were first fractionated by high-pH high-pressure liquid chromatography and then subjected to separation by nano-liquid chromatography (nano-LC)–mass spectrometry (MS) at low pH. Approximately 10 million ions were selected for sequencing by tandem mass spectrometry (MS/MS). HLA-A*11:01 ligand sequences were determined with PEAKS software and confirmed by comparison to spectra generated from synthetic peptides. DLS identified 42 viral ligands presented by HLA-A*11:01, and 37 of these were previously undetected. These data demonstrate that (i) HIV-1 Gag and Nef are extensively sampled, (ii) ligand length variants are prevalent, particularly within Gag and Nef hot spots where ligand sequences overlap, (iii) noncanonical ligands are T cell reactive, and (iv) HIV-1 ligands are derived from de novo synthesis rather than endocytic sampling. Next-generation immunotherapies must factor these nascent HIV-1 ligand length variants and the finding that CTL-reactive epitopes may be absent during infection of CD4+ T cells into strategies designed to enhance T cell immunity. IMPORTANCE HIV-1 epitopes catalogued by the Los Alamos National Laboratory (LANL) have yielded limited success in vaccine trials. Because the HLA of infected cells have not previously been assessed for HIV-1 ligands, the objective here was to directly characterize the viral ligands that mark infected cells. Recovery of HLA-presented peptides from HIV-1-infected CD4+ T cells and interrogation of the peptide cargo by mass spectrometric DLS show that typical and atypical viral ligands are efficiently presented by HLA and targeted by human CTLs. Nef and Gag ligands dominate the infected cell's antigenic profile, largely due to extensive ligand sampling from select hot spots within these viral proteins. Also, HIV-1 ligands are often longer than expected, and these length variants are quite antigenic. These findings emphasize that an HLA-based view of HIV-1 ligand presentation to CTLs provides previously unrealized information that may enhance the development of immune therapies and vaccines.

[1]  M. Bouvier,et al.  A biochemical and structural analysis of genetic diversity within the HLA-A*11 subtype , 2005, Immunogenetics.

[2]  W. Hildebrand,et al.  Direct class I HLA antigen discovery to distinguish virus-infected and cancerous cells , 2006, Expert review of proteomics.

[3]  Victor Appay,et al.  A molecular basis for the control of preimmune escape variants by HIV-specific CD8+ T cells. , 2013, Immunity.

[4]  J. Prado,et al.  Early Antigen Presentation of Protective HIV-1 KF11Gag and KK10Gag Epitopes from Incoming Viral Particles Facilitates Rapid Recognition of Infected Cells by Specific CD8+ T Cells , 2012, Journal of Virology.

[5]  M. Emerman,et al.  Detection of replication-competent and pseudotyped human immunodeficiency virus with a sensitive cell line on the basis of activation of an integrated beta-galactosidase gene , 1992, Journal of virology.

[6]  P. Doherty,et al.  Differential Antigen Presentation Regulates the Changing Patterns of CD8+ T Cell Immunodominance in Primary and Secondary Influenza Virus Infections , 2003, The Journal of experimental medicine.

[7]  Anuska Llano,et al.  Best-Characterized HIV-1 CTL Epitopes: The 2013 Update , 2013 .

[8]  M. Diamond,et al.  A novel T‐cell receptor mimic defines dendritic cells that present an immunodominant West Nile virus epitope in mice , 2014, European journal of immunology.

[9]  D. Montefiori,et al.  Lymph node T cell responses predict the efficacy of live attenuated SIV vaccines , 2012, Nature Medicine.

[10]  David Heckerman,et al.  Control of human immunodeficiency virus replication by cytotoxic T lymphocytes targeting subdominant epitopes , 2006, Nature Immunology.

[11]  James McCluskey,et al.  Have we cut ourselves too short in mapping CTL epitopes? , 2006, Trends in immunology.

[12]  E. Rosenberg,et al.  Comprehensive Analysis of Human Immunodeficiency Virus Type 1-Specific CD4 Responses Reveals Marked Immunodominance of gag and nef and the Presence of Broadly Recognized Peptides , 2004, Journal of Virology.

[13]  W. Hildebrand,et al.  Critical factors in the development of fluorescence polarization-based peptide binding assays: an equilibrium study monitoring specific peptide binding to soluble HLA-A*0201. , 2006, Journal of immunological methods.

[14]  S. Oka,et al.  Different In Vivo Effects of HIV-1 Immunodominant Epitope-Specific Cytotoxic T Lymphocytes on Selection of Escape Mutant Viruses , 2010, Journal of Virology.

[15]  E. Bunnik,et al.  Escape from autologous humoral immunity of HIV-1 is not associated with a decrease in replicative capacity. , 2010, Virology.

[16]  H. Schuitemaker,et al.  Correlates of resistance to HIV-1 infection in homosexual men with high-risk sexual behaviour , 2004, AIDS.

[17]  Development of prophylactic vaccines against HIV-1 , 2013, Retrovirology.

[18]  B. Walker,et al.  HLA-B57-Restricted Cytotoxic T-Lymphocyte Activity in a Single Infected Subject toward Two Optimal Epitopes, One of Which Is Entirely Contained within the Other , 2000, Journal of Virology.

[19]  Matthew S. Lewis,et al.  Profound early control of highly pathogenic SIV by an effector-memory T cell vaccine , 2011, Nature.

[20]  David Heckerman,et al.  Adaptation of HIV-1 to human leukocyte antigen class I , 2009, Nature.

[21]  Wilfried Bardet,et al.  Development and validation of a fluorescence polarization-based competitive peptide-binding assay for HLA-A*0201--a new tool for epitope discovery. , 2005, Biochemistry.

[22]  Todd M. Allen,et al.  TCR clonotypes modulate the protective effect of HLA class I molecules in HIV-1 infection , 2012, Nature Immunology.

[23]  R. Sanders,et al.  Broadly neutralizing antibodies against HIV-1: templates for a vaccine. , 2013, Virology.

[24]  S. Swaminathan,et al.  Short communication: association of HLA-A*1101 with resistance and B*4006 with susceptibility to HIV and HIV-TB: an in silico analysis of promiscuous T cell epitopes. , 2009, AIDS research and human retroviruses.

[25]  E. Bunnik,et al.  Cross-reactive neutralizing humoral immunity does not protect from HIV type 1 disease progression. , 2010, The Journal of infectious diseases.

[26]  Kyle B. Bond,et al.  HIV-specific cytotoxic T lymphocytes, HLA-A11, and chemokine-related factors may act synergistically to determine HIV resistance in CCR5 delta32-negative female sex workers in Chiang Rai, northern Thailand. , 2001, AIDS research and human retroviruses.

[27]  K. Collins,et al.  Adaptor Protein 1 Promotes Cross-Presentation through the Same Tyrosine Signal in Major Histocompatibility Complex Class I as That Targeted by HIV-1 , 2013, Journal of Virology.

[28]  P. Rouger,et al.  HLA-associated susceptibility to acquired immune deficiency syndrome in HIV-1-seropositive subjects. , 1990, Human heredity.

[29]  T. Kotsimbos,et al.  Refinement in the production and purification of recombinant HCMV IE1-pp65 protein for the generation of epitope-specific T cell immunity. , 2008, Protein expression and purification.

[30]  Galit Alter,et al.  De Novo Generation of Escape Variant-Specific CD8+ T-Cell Responses following Cytotoxic T-Lymphocyte Escape in Chronic Human Immunodeficiency Virus Type 1 Infection , 2005, Journal of Virology.

[31]  Wilfried Bardet,et al.  Real-time measurement of in vitro peptide binding to soluble HLA-A*0201 by fluorescence polarization. , 2004, Biochemistry.

[32]  Matthew S. Lewis,et al.  Immune clearance of highly pathogenic SIV infection , 2013, Nature.

[33]  R. Dolin,et al.  Novel HIV vaccine strategies: overview and perspective , 2013, Therapeutic advances in vaccines.

[34]  J. Mullins,et al.  Impact of Mutations in Highly Conserved Amino Acids of the HIV-1 Gag-p24 and Env-gp120 Proteins on Viral Replication in Different Genetic Backgrounds , 2014, PloS one.

[35]  Todd M. Allen,et al.  Definition of the viral targets of protective HIV-1-specific T cell responses , 2011, Journal of Translational Medicine.

[36]  B. Walker,et al.  HIV and HLA class I: an evolving relationship. , 2012, Immunity.

[37]  L. Picker,et al.  CD4+ T‐cell depletion in HIV infection: mechanisms of immunological failure , 2013, Immunological reviews.